Conivaptan

125 interactions 11 explained in plain English
Also sold as: Vaprisol
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ivabradine Alfuzosin Maraviroc Lurasidone Colchicine Ketoconazole Topical
7 Contraindicated 116 Major 2 Moderate
All (125) Contraindicated (7) Major (116) Moderate (2)

Contraindicated

Conivaptan Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine toxicity Details Conivaptan Alfuzosin UroXatral Increased alfuzosin exposure Details Conivaptan Ivabradine Corlanor Increased ivabradine exposure Details Conivaptan Ketoconazole Topical Extina® Foam Increased conivaptan exposure and an increased CYP3A substrate exposure Details Conivaptan Lurasidone Latuda Increased lurasidone exposure Details Conivaptan Maraviroc Selzentry Increased maraviroc exposure Details Conivaptan Nimodipine Nimotop Increased serum nimodipine concentrations Details

Major

Conivaptan Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Conivaptan Clindamycin ANTIROBE Explained Increased CYP3A substrate exposure Details Conivaptan Omeprazole Gastrobim Explained Increased CYP3A substrate exposure Details Conivaptan Sertraline Explained Increased CYP3A substrate exposure Details Conivaptan Buprenorphine Belbuca Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Conivaptan Simvastatin Flolipid Explained Increased CYP3A substrate exposure Details Conivaptan Acalabrutinib Calquence Increased acalabrutinib exposure Details Conivaptan Ado-Trastuzumab Emtansine Injection KADCYLA Increased exposure of cytotoxic component DM1 (maytansine derivative) and risk of toxicity Details Conivaptan Apixaban Eliquis Explained Increased CYP3A substrate exposure Details Conivaptan Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Conivaptan Avapritinib Ayvakit Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Conivaptan Avatrombopag Doptelet Increased CYP3A substrate exposure Details Conivaptan Belumosudil Rezurock Explained Increased CYP3A substrate exposure Details Conivaptan Betrixaban Bevyxxa® Increased betrixaban exposure and increased risk of bleeding Details Conivaptan Atorvastatin Atorvaliq Increased CYP3A substrate exposure Details Conivaptan Cariprazine Vraylar Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Conivaptan Abiraterone Abirtega Increased CYP3A substrate exposure Details Conivaptan Afatinib Gilotrif Increased exposure of afatinib Details Conivaptan Amlodipine Amvaz® Increased CYP3A substrate exposure Details Conivaptan Avanafil Stendra Reduced avanafil clearance and increased avanafil exposure Details Conivaptan Axitinib Inlyta Increased CYP3A substrate exposure Details Conivaptan Bedaquiline Sirturo Increased CYP3A substrate exposure Details Conivaptan Bosutinib Bosulif Increased CYP3A substrate exposure Details Conivaptan Brexpiprazole Rexulti Increased brexpiprazole exposure Details Conivaptan Brigatinib Alunbrig Increased brigatinib exposure Details Conivaptan Budesonide Entocort Increased CYP3A substrate exposure Details Conivaptan Budesonide Nasal Spray Rhinocort Increased CYP3A substrate exposure Details Conivaptan Budesonide Oral Inhalation Pulmicort Increased CYP3A substrate exposure Details Conivaptan Cabazitaxel Injection Jevtana Increased cabazitaxel exposure Details Conivaptan Cabozantinib Cabometyx Increased cabozantinib exposure Details Conivaptan Cabozantinib (Thyroid Cancer) Cabometyx Increased cabozantinib exposure Details Conivaptan Calcifediol Rayaldee Altered serum levels of calcifediol Details Conivaptan Capmatinib Tabrecta Increased CYP3A substrate exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.